Literature DB >> 16191510

Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.

Sergej Konoplev1, L Jeffrey Medeiros, Carlos E Bueso-Ramos, Jeffrey L Jorgensen, Pei Lin.   

Abstract

We retrospectively reviewed the immunophenotypic profile of 75 cases of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) analyzed by flow cytometry. All patients had monoclonal IgM (median, 2,100 mg/dL [21 g/L]) in serum and were considered clinically to have WM. The neoplastic cells, in all cases, expressed monoclonal immunoglobulin light chain (k, 55; l, 20) and CD19, and every case assessed was positive for CD20 (n=68) and CD52 (n=60). The results for other antigens assessed in decreasing frequency of positivity were as follows: surface IgM (26/28 [93%]), CD79b (11/13 [85%]), CD11c (13/16 [81%]), CD25 (5/7 [71%]), CD23 (17/28 [61%]), CD38 (24/50 [48%]), FMC7 (11/29 [38%]), CD22 (4/12 [33%]), CD5 (3/65 [5%]), and CD10 (1/38 [3%]). These results show that the immunophenotype of LPL/WM is variable and overlaps with other B-cell lymphoproliferative disorders. CD23, usually of dim intensity, and CD11c are expressed commonly in LPL/WM. Rare CD5+ and CD10+ cases of LPL/WM also exist.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16191510     DOI: 10.1309/3G1X-DX0D-VHBN-VKB4

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  28 in total

1.  Persistent monotypic plasma cells with absence of neoplastic B cell component in a treated case of waldenström macroglobulinemia: a sign of residual disease?

Authors:  Smeeta Gajendra; Ritesh Sachdev; Bhawna Jha; Shalini Goel; Tushar Sahni
Journal:  J Clin Diagn Res       Date:  2014-11-20

2.  Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification.

Authors:  B Paiva; M C Montes; R García-Sanz; E M Ocio; J Alonso; N de Las Heras; F Escalante; R Cuello; A G de Coca; J Galende; J Hernández; M Sierra; A Martin; E Pardal; A Bárez; J Alonso; L Suarez; T J González-López; J J Perez; A Orfao; M-B Vidríales; J F San Miguel
Journal:  Leukemia       Date:  2013-04-22       Impact factor: 11.528

3.  CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases.

Authors:  Yu Li; Shimin Hu; Zhuang Zuo; Ming Hong; Pei Lin; Shaoying Li; Sergej Konoplev; Zhen Wang; Joseph D Khoury; Ken H Young; L Jeffrey Medeiros; C Cameron Yin
Journal:  Mod Pathol       Date:  2015-03-06       Impact factor: 7.842

4.  Requirement of CXCL12-CXCR7 signaling for CD20(-) CD138(-) double-negative population in lymphoplasmacytic lymphoma.

Authors:  Naoki Wada; Jun-Ichiro Ikeda; Satoshi Nojima; Shin-Ichiro Tahara; Kenji Ohshima; Daisuke Okuzaki; Eiichi Morii
Journal:  Lab Invest       Date:  2016-02-15       Impact factor: 5.662

5.  Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells.

Authors:  Kasyapa Chitta; Aneel Paulus; Sharoon Akhtar; Maja Kristin K Blake; Thomas R Caulfield; Anne J Novak; Stephen M Ansell; Pooja Advani; Sikander Ailawadhi; Taimur Sher; Stig Linder; Asher Chanan-Khan
Journal:  Br J Haematol       Date:  2015-02-17       Impact factor: 6.998

6.  Clinicopathologic significance of loss of CD19 expression in diffuse large B-cell lymphoma.

Authors:  Miho Kimura; Motoko Yamaguchi; Shigeo Nakamura; Hiroshi Imai; Satoshi Ueno; Shoko Ogawa; Kana Miyazaki; Kouji Oka; Toshiyuki Ohno; Kenkichi Kita; Tohru Kobayashi; Hiroshi Shiku
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

7.  A case of AL amyloidosis associated with follicular lymphoma with plasmacytic differentiation.

Authors:  Yosuke Matsumoto; Tetsuya Masuda; Ayako Nishimura; Hideki Horie; Kenichi Harada; Mihoko Yoshida; Kazuho Shimura; Hiroto Kaneko; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2019-09-21       Impact factor: 2.490

8.  Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.

Authors:  Prashant R Tembhare; Constance M Yuan; David Venzon; Raul Braylan; Neha Korde; Elisabet Manasanch; Diamond Zuchlinsky; Katherine Calvo; Roger Kurlander; Manisha Bhutani; Nishant Tageja; Irina Maric; Marcia Mulquin; Mark Roschewski; Mary Kwok; David Liewehr; Ola Landgren; Maryalice Stetler-Stevenson
Journal:  Leuk Res       Date:  2013-12-11       Impact factor: 3.156

9.  High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders.

Authors:  Antonella Caivano; Ilaria Laurenzana; Luciana De Luca; Francesco La Rocca; Vittorio Simeon; Stefania Trino; Fiorella D'Auria; Antonio Traficante; Maddalena Maietti; Tiziana Izzo; Giovanni D'Arena; Giovanna Mansueto; Giuseppe Pietrantuono; Luca Laurenti; Pellegrino Musto; Luigi Del Vecchio
Journal:  Tumour Biol       Date:  2015-07-09

10.  Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.

Authors:  Aneel Paulus; Alak Manna; Sharoon Akhtar; Shumail M Paulus; Mayank Sharma; Marie V Coignet; Liuyan Jiang; Vivek Roy; Thomas E Witzig; Stephen M Ansell; John Allan; Richard Furman; Sonikpreet Aulakh; Rami Manochakian; Sikander Ailawadhi; Asher A Chanan-Khan; Taimur Sher
Journal:  Br J Haematol       Date:  2018-08-06       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.